Literature DB >> 2046941

Complete ophthalmoplegia as a complication of acute corticosteroid- and pancuronium-associated myopathy.

L D Sitwell1, B G Weinshenker, V Monpetit, D Reid.   

Abstract

We report acute complete external ophthalmoplegia and severe myopathy in a patient treated with high doses of IV methylprednisolone and pancuronium. Awareness of this rare syndrome in a common clinical setting can lead to prompt recognition and avoid confusion with other causes of acute weakness and ophthalmoparesis.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 2046941     DOI： 10.1212/wnl.41.6.921

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  6 in total

Review 1.  [Intensive care unit acquired weakness. Pathogenesis, treatment, rehabilitation and outcome].

Authors:  M Ponfick; K Bösl; J Lüdemann-Podubecka; G Neumann; M Pohl; D A Nowak; H-J Gdynia
Journal:  Nervenarzt       Date:  2014-02       Impact factor: 1.214

Review 2.  Acute neuromuscular respiratory paralysis.

Authors:  R A Hughes; D Bihari
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-04       Impact factor: 10.154

Review 3.  Mitochondrial changes in acute myopathy after treatment of respiratory failure with mechanical ventilation (acute relaxant-steroid myopathy).

Authors:  S Matsubara; T Okada; M Yoshida
Journal:  Acta Neuropathol       Date:  1994       Impact factor: 17.088

Review 4.  The Sick and the Weak: Neuropathies/Myopathies in the Critically Ill.

Authors:  O Friedrich; M B Reid; G Van den Berghe; I Vanhorebeek; G Hermans; M M Rich; L Larsson
Journal:  Physiol Rev       Date:  2015-07       Impact factor: 37.312

5.  Acute quadriparesis in an asthmatic treated with atracurium.

Authors:  C P Tousignant; D R Bevan; A A Eisen; J C Fenwick; M G Tweedale
Journal:  Can J Anaesth       Date:  1995-03       Impact factor: 5.063

Review 6.  Approach to neuromuscular disorders in the intensive care unit.

Authors:  Kenneth C Gorson
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.